Document Detail


Chronic administration of carvedilol improves cardiac function in 6-month-old Syrian cardiomyopathic hamsters.
MedLine Citation:
PMID:  17534124     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Heart failure (HF) is a multifactorial and progressive disease that has been linked to activation of the renin-angiotensin and sympathetic systems. In recent years, beta-blockers have been shown to improve the status of HF patients, although the precise mechanisms remain unclear. The present study evaluates the effect of beta-blockade with carvedilol (1 mg/kg/day) on cardiovascular function in 2- and 6-month-old cardiomyopathic hamsters (SCH) after 1-month and 5-month treatment periods with the drug, respectively. Age-matched golden hamsters were used as controls (CT). Systolic blood pressure (SBP) and echocardiographic studies were evaluated. The latter studies included left ventricular end-systolic (LVESV) and end-diastolic (LVEDV) volumes, ejection fraction (EF), cardiac output index (COI), heart rate (HR), and left ventricular posterior wall thickness (LVPWT). In 2-month-old SCH, carvedilol administration during a 1-month period reduced SBP from 107.59 +/- 3.49 to 77.26 +/- 3.49 mm Hg (n = 5, p < 0.05). At this stage, cardiac parameters in SCH were similar to those of controls and were not affected by carvedilol administration. In 6-month-old SCH, 5-month administration of carvedilol decreased SBP from 102.16 +/- 3.61 to 90.60 +/- 2.80 mm Hg (n = 5, p < 0.05), HR from 363 +/- 14 to 324 +/- 14 bpm (n = 5, p < 0.05), and LVESV from 0.18 +/- 0.01 to 0.13 +/- 0.01 ml/100 g BW (n = 5, p < 0.05), and increased EF and COI by 14 and 23%, respectively (n = 5, p < 0.05). The drug did not modify LVEDV or LVPWT. These results reveal that carvedilol significantly improves cardiac function in 6-month-old cardiomyopathic hamsters, but it does not prevent ventricular dilatation. Improved cardiac function appears to be secondary to decreased total peripheral resistance, due mainly to the vasodilator properties of the drug. Thus, overactivation of the sympathetic system is not likely to be a determining factor in the etiology of dilated cardiomyopathy in this animal model.
Authors:
Nildris Cruz; Luz Arocho; Luis Rosario; Maria J Crespo
Related Documents :
2576194 - Blood pressure lowering action and alpha-adrenolytic effect of adimolol in rats.
17440824 - Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure.
24920204 - Quality of life and self-esteem in patients with paraplegia and pressure ulcers: a cont...
3094 - Comparison between metoprolol and propranolol as antihypertensive agents. a double-blin...
7137464 - Effects of intraluminal pressure on regional blood flow in obstructed and unobstructed ...
16249674 - Neutrophil stimulation with granulocyte colony-stimulating factor worsens ventilator-in...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2007-05-29
Journal Detail:
Title:  Pharmacology     Volume:  80     ISSN:  0031-7012     ISO Abbreviation:  Pharmacology     Publication Date:  2007  
Date Detail:
Created Date:  2007-08-08     Completed Date:  2007-10-04     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  0152016     Medline TA:  Pharmacology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  144-50     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2007 S. Karger AG, Basel.
Affiliation:
Department of Physiology, School of Medicine, University of Puerto Rico, San Juan, P.R., USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / administration & dosage,  pharmacology*
Animals
Blood Pressure / drug effects
Carbazoles / administration & dosage,  pharmacology*
Cardiac Output / drug effects
Cardiomyopathies / pathology,  physiopathology,  prevention & control*
Cricetinae
Disease Models, Animal
Echocardiography, Doppler
Heart Rate / drug effects
Male
Mesocricetus
Propanolamines / administration & dosage,  pharmacology*
Vasodilation / drug effects
Vasodilator Agents / administration & dosage,  pharmacology*
Grant Support
ID/Acronym/Agency:
2 S06 GM08224/GM/NIGMS NIH HHS; RR-03051/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Carbazoles; 0/Propanolamines; 0/Vasodilator Agents; 0K47UL67F2/carvedilol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Resveratrol-induced apoptosis is associated with activation of p53 and inhibition of protein transla...
Next Document:  Strychnine-sensitive glycine receptors mediate the analgesic but not hypnotic effects of emulsified ...